Alpha-dihydroergocryptine in Parkinson's disease: a multicentre randomized double blind parallel group study

Area of Science:

• Neurology
• Pharmacology

Background:

• Idiopathic Parkinson's disease (PD) patients on L-dopa therapy often experience inadequate response and motor complications.
• A study investigated adjunct therapies for L-dopa treated PD patients with insufficient therapeutic responsiveness.

Purpose of the Study:

• To compare the efficacy of alpha-dihydroergocryptine (alpha-DHEC) versus lisuride as adjunct therapy to L-dopa.
• To assess the impact on dyskinesias, clinical fluctuations, symptom patterns, and disability.
• To evaluate the incidence of adverse events associated with each adjunct therapy.

Main Methods:

• A multicentre, randomized, double-blind, parallel-group study involving 68 PD patients.
• Patients were randomized to receive either alpha-DHEC or lisuride as adjunct therapy to L-dopa for 3 months.
• Dosages were titrated to 60 mg/day for alpha-DHEC and 1.2 mg/day for lisuride, with L-dopa dosage remaining constant.

Main Results:

• Both alpha-DHEC and lisuride significantly improved PD symptoms when used as adjuncts to L-dopa.
• Alpha-dihydroergocryptine demonstrated superior efficacy in reducing clinical motor complications (P < 0.01).
• Adverse events were reported in 25% of patients on alpha-DHEC versus 67% on lisuride (P < 0.05).

Conclusions:

• Alpha-dihydroergocryptine appears more effective than lisuride in mitigating long-term motor complications associated with L-dopa therapy in Parkinson's disease.
• Alpha-dihydroergocryptine also showed a lower incidence and severity of adverse events compared to lisuride.